HRP20200357T1 - Spojevi 2,6-diokso,-2,3-dihidro-1h-purina, korisni u liječenju poremećaja povezanih s aktivnošću kanala trpa1 - Google Patents
Spojevi 2,6-diokso,-2,3-dihidro-1h-purina, korisni u liječenju poremećaja povezanih s aktivnošću kanala trpa1 Download PDFInfo
- Publication number
- HRP20200357T1 HRP20200357T1 HRP20200357TT HRP20200357T HRP20200357T1 HR P20200357 T1 HRP20200357 T1 HR P20200357T1 HR P20200357T T HRP20200357T T HR P20200357TT HR P20200357 T HRP20200357 T HR P20200357T HR P20200357 T1 HRP20200357 T1 HR P20200357T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- substituted
- carbocyclyl
- Prior art date
Links
- 102000012253 TRPA1 Cation Channel Human genes 0.000 title 1
- 108010036769 TRPA1 Cation Channel Proteins 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 206010068065 Burning mouth syndrome Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- -1 amino, amidyl Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010070237 Burning feet syndrome Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 1
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000035617 depilation Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 125000005864 sulfonamidyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/105—Persulfides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (4)
1. Spoj formule (VIII′)
[image]
,
naznačen time što:
L je C(O)NR6;
R3a je 6-eročlani heteroaril, izborno supstituiran s 1-4 R7;
R3b je karbociklil, heterociklil, aril ili heteroaril, od kojih svaki može biti supstituiran s 1-4 R7;
svaki R6 je neovisno H, C1-C6 alkil, C1-C6 alkenil, hidroksiC1-C6 alkil, alkoksiC1-C6 alkil, cijanoalkil, halogenalkil, arilalkil, S(O)alkil, acil, amino, amidil, S(O)2H, aril ili alkoksiaril;
svaki R7 je neovisno C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, halogen, hidroksil, alkoksi, okso, aril, heteroaril, karbociklil, heterociklil, arilalkil, heteroarilalkil, ciklilalkil, heterociklilalkil, ariloksi, arilalkoksi, amino, akilamino, dialkilamino, tioil, alkiltioil, sulfonil, sulfonamidil, amido (primjerice gdje je dušik iz amida supstituiran alkilom, ili gdje dušik iz amida, zajedno s dva ugljika na koje je vezan, tvori prsten), hidroksil alkoksil, alkoksi -C(O)OH, -C(O)Oalkil, urea, sulfonilurea, acil, nitro ili cijano, od kojih svaki može biti supstituiran s 1-3 R8;
svaki R8 je neovisno C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, aril, heteroaril, karbociklil, halogen, hidroksil, alkoksi, okso, ariloksi, amino, akilamino, dialkilamino, C(O)OH, -C(O)Oalkil, tioil, sulfonil, sulfonamidil, amido (primjerice gdje je dušik iz amida supstituiran alkilom, ili gdje dušik iz amida, zajedno s dva ugljika na koje je vezan, tvori prsten), urea, sulfonilurea, acil, nitro, cijano, karbociklil, heterociklil, aril ili heteroaril.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R3a heteroaril koji sadrži dušik.
3. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je R3b supstituiran s 1-4 R7.
4. Spoj formule (VIII′) u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja kod kojeg posreduje TRPA1 kojeg se bira iz skupine koju čine akutna i/ili kronična bol, osjetljivost na dodir, opekline, upala, dijabetična neuropatija, psorijaza, egzem, dermatitis, postherpetična neuralgija, migrena, inkontinencija, groznica, napadaji vrućine, osteoartritis, oralni mukozitis, bol uzrokovana rakom, cistitis mokraćnog mjehura, bol povezana s Crohnovom bolešću i sindrom iritabilnih crijeva (IBS), reumatoidni artritis, Grierson-Gopalanov sindrom, sindrom pečenja u ustima (BMS) i kašalj, ili kod depilacije radi poticanja gubitka ili inhibiranja rasta dlaka kod pacijenta.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94584007P | 2007-06-22 | 2007-06-22 | |
US94586607P | 2007-06-22 | 2007-06-22 | |
EP16195618.0A EP3184527B1 (en) | 2007-06-22 | 2008-06-23 | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200357T1 true HRP20200357T1 (hr) | 2020-06-12 |
Family
ID=40186010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200357TT HRP20200357T1 (hr) | 2007-06-22 | 2020-03-03 | Spojevi 2,6-diokso,-2,3-dihidro-1h-purina, korisni u liječenju poremećaja povezanih s aktivnošću kanala trpa1 |
Country Status (11)
Country | Link |
---|---|
US (3) | US8163761B2 (hr) |
EP (3) | EP3184527B1 (hr) |
JP (5) | JP2010530901A (hr) |
CN (4) | CN101801362B (hr) |
AU (1) | AU2008268463B2 (hr) |
CA (2) | CA2691468C (hr) |
DK (1) | DK2170309T3 (hr) |
ES (1) | ES2609912T3 (hr) |
HR (1) | HRP20200357T1 (hr) |
SI (1) | SI3184527T1 (hr) |
WO (1) | WO2009002933A1 (hr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
WO2009140517A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2009140519A1 (en) * | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2010039289A2 (en) | 2008-05-14 | 2010-04-08 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
US7951814B2 (en) | 2008-06-17 | 2011-05-31 | Glenmark Pharmaceuticals, S.A. | Quinazolinedione derivatives as TRPA1 modulators |
WO2010077976A2 (en) | 2008-12-17 | 2010-07-08 | The Regents Of The University Of California | Prokineticin receptor antagonists and uses thereof |
US8362025B2 (en) | 2008-12-22 | 2013-01-29 | Hydra Biosciences, Inc. | Compositions useful for treating disorders related to TRPA1 |
PT2411395E (pt) * | 2009-03-23 | 2013-06-06 | Glenmark Pharmaceuticals Sa | Derivados de furopirimidinadiona como moduladores de trpa1 |
US8623880B2 (en) | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
DK2411397T3 (da) | 2009-03-23 | 2013-08-05 | Glenmark Pharmaceuticals Sa | Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 |
ES2456515T3 (es) * | 2009-03-23 | 2014-04-22 | Glenmark Pharmaceuticals S.A. | Derivados de pirimidindiona fusionados como moduladores de TRPA1 |
WO2011026917A1 (en) * | 2009-09-04 | 2011-03-10 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
AP3391A (en) | 2010-12-20 | 2015-08-31 | Glenmark Pharmaceuticals Sa | 2-Amino-4-arylthiazole compounds as TROA1 antagonists |
WO2012098281A2 (es) | 2011-01-19 | 2012-07-26 | Universidad Miguel Hernández De Elche | Péptidos moduladores de receptores trp y sus usos |
CA2836856A1 (en) | 2011-06-13 | 2012-12-20 | Glenmark Pharmaceuticals, S.A. | Treatment of respiratory disorders using trpa1 antagonists |
WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
JP2014517062A (ja) | 2011-06-22 | 2014-07-17 | グレンマーク ファーマシューティカルズ, エセ.アー. | TRPA1アンタゴニスト及びβ2アゴニストを含む医薬組成物 |
CA2841417A1 (en) * | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
AR087501A1 (es) * | 2011-08-09 | 2014-03-26 | Hydra Biosciences Inc | Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 |
EP2787991A1 (en) | 2011-12-05 | 2014-10-15 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
US9962430B2 (en) | 2012-02-15 | 2018-05-08 | Chirhoclin, Inc. | Methods for treating pain associated with chronic pancreatitis |
US9499533B2 (en) | 2012-03-27 | 2016-11-22 | Shionogi & Co., Ltd. | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity |
US11406718B2 (en) | 2012-05-29 | 2022-08-09 | Chirhoclin, Inc. | Methods of detecting pancreobiliary ductal leaks |
US9221821B2 (en) | 2012-06-05 | 2015-12-29 | Forest Laboratories Holdings, Limited | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds |
CA2873570C (en) * | 2012-06-08 | 2016-11-01 | Glenmark Pharmaceuticals S.A. | Amides of 2-amino-4-arylthiazole compounds and their salts as trpa1 modulators |
US20140163048A1 (en) * | 2012-08-09 | 2014-06-12 | Cubist Pharmaceuticals, Inc. | Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1 |
CA2893597C (en) | 2012-12-07 | 2021-06-29 | Chemocentryx, Inc. | Diazole lactams |
US9169248B2 (en) | 2012-12-21 | 2015-10-27 | Chemocentryx, Inc. | Diazole amides |
US9394308B2 (en) | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
TW201441225A (zh) * | 2013-01-18 | 2014-11-01 | Cubist Pharm Inc | 瞬時受體電位a1離子通道之抑制 |
GB201309333D0 (en) * | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
CN105518005B (zh) | 2013-07-02 | 2018-07-20 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
CN105492444B (zh) | 2013-07-02 | 2018-09-07 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
AU2014335868A1 (en) | 2013-10-15 | 2016-05-05 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent |
CN103837612B (zh) * | 2013-11-03 | 2016-10-05 | 黑龙江福和华星制药集团股份有限公司 | 多索茶碱注射液有关物质测定方法 |
CN103788095A (zh) * | 2014-01-20 | 2014-05-14 | 四川大学华西医院 | 2,4(1h,3h)-嘧啶二酮衍生物及其制备方法 |
WO2015134790A1 (en) * | 2014-03-07 | 2015-09-11 | Sanford-Burnham Medical Research Institute | Small molecule fatty acid synthase inhibitors |
TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位a1離子通道 |
US20190175599A1 (en) | 2014-09-16 | 2019-06-13 | Glemark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
PL3193880T3 (pl) * | 2014-09-19 | 2020-09-07 | Eli Lilly And Company | Hamowanie kanału jonowego receptora przejściowego potencjału A1 |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
PT3439653T (pt) | 2016-04-07 | 2021-03-25 | Chemocentryx Inc | Redução da carga tumoral por administração de antagonistas de ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
JP6788476B2 (ja) | 2016-10-21 | 2020-11-25 | 株式会社ミツトヨ | クロマティック共焦点センサ及び測定方法 |
US20190374552A1 (en) * | 2016-11-02 | 2019-12-12 | George Edward Hoag | Multifunctional formulations and methods to control dermatitis and pruritus |
CN110461838B (zh) * | 2017-03-07 | 2022-05-06 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
EP3746445A1 (en) | 2018-01-31 | 2020-12-09 | Eli Lilly And Company | Inhibiting the transient receptor potential a1 ion channel |
US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
CN108997350B (zh) * | 2018-07-03 | 2021-03-02 | 南昌立德生物技术有限公司 | 一种周期蛋白依赖性激酶8抑制剂 |
JP2022527438A (ja) | 2019-03-11 | 2022-06-02 | ノシオン セラピューティクス,インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
WO2020185881A1 (en) | 2019-03-11 | 2020-09-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US10927096B2 (en) | 2019-03-11 | 2021-02-23 | Nocion Therapeutics, Inc. | Ester substituted ion channel blockers and methods for use |
US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
CN110343759A (zh) * | 2019-06-03 | 2019-10-18 | 张鹏 | Trpv4的用途及其抑制剂的用途和药物筛选方法 |
CN110526878A (zh) * | 2019-09-16 | 2019-12-03 | 成都睿智化学研究有限公司 | 一种2-(噁唑基)乙胺的制备方法 |
CN112691094B (zh) * | 2019-10-22 | 2022-09-23 | 中国科学院分子细胞科学卓越创新中心 | 防治病毒的新型化合物及其应用 |
WO2021091586A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
JP2023500891A (ja) | 2019-11-06 | 2023-01-11 | ノシオン セラピューティクス,インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
US11332446B2 (en) | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US11744878B2 (en) | 2020-08-19 | 2023-09-05 | Chirhoclin, Inc. | Methods for treatment of COVID-19 syndrome |
EP4079304A1 (en) * | 2021-04-21 | 2022-10-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Compounds for use in the treatment of hyperproliferative disorders |
CN114671875A (zh) * | 2022-04-27 | 2022-06-28 | 成都施贝康生物医药科技有限公司 | 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途 |
US11951082B2 (en) | 2022-08-22 | 2024-04-09 | Ford Therapeutics, Llc | Composition of chlorhexidine |
CN116655635B (zh) * | 2023-05-19 | 2024-01-26 | 济南爱思医药科技有限公司 | 黑茶茶碱衍生物及在制备药物中的应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599337A (en) * | 1977-08-09 | 1986-07-08 | Eisai Co., Ltd. | Antiphlogistic/antipyretic/analgesic agents containing theobromine or theophylline derivatives as active ingredient |
US4426383A (en) * | 1980-09-04 | 1984-01-17 | Eisai Co., Ltd. | Theophylline and theobromine derivatives |
DE3307395A1 (de) * | 1982-03-02 | 1983-09-08 | Eisai Co., Ltd., Tokyo | Arzneimittel zur behandlung von schmerzen, fieber, gewebe- und/oder knochen- und gelenkentzuendungen mit einem gehalt an theobromin- oder theophyllinderivaten als aktivem bestandteil |
HU190377B (en) * | 1982-03-12 | 1986-08-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing theophyllinyl-alkyl-oxadiazoles |
US4548939A (en) * | 1984-10-01 | 1985-10-22 | Janssen Pharmaceutica N. V. | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones |
GB9524812D0 (en) | 1995-12-05 | 1996-02-07 | Leo Pharm Prod Ltd | Chemical compounds |
FR2761068B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique |
US20030199693A1 (en) * | 2000-07-28 | 2003-10-23 | Ing-Jun Chen | Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activies on PDE-5 phosphodiesterase |
US7818808B1 (en) | 2000-12-27 | 2010-10-19 | Intel Corporation | Processor mode for limiting the operation of guest software running on a virtual machine supported by a virtual machine monitor |
GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
BR0302965A (pt) * | 2002-02-01 | 2005-02-09 | King Pharmaceuticals Res & Dev | Composto e método de tratar doenças mediadas por receptores de adenosina a2b |
EP1546377A4 (en) * | 2002-02-28 | 2006-07-19 | Millennium Pharm Inc | METHODS AND COMPOSITIONS FOR TREATING PAIN AND PAIN DISORDERS USING MOLECULES 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 OR 13424 |
GB0213869D0 (en) * | 2002-06-17 | 2002-07-31 | Arakis Ltd | The treatment of pain |
US20050209243A1 (en) * | 2002-09-27 | 2005-09-22 | Ing-Jun Chen | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities |
US20070196866A1 (en) | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
KR20060129411A (ko) * | 2004-03-30 | 2006-12-15 | 패러다임 테라퓨틱스 리미티드 | 이온 채널 |
CA2549577A1 (en) | 2004-09-09 | 2006-03-16 | Avaya Technology Corp. | Methods of and systems for network traffic security |
US20070021992A1 (en) * | 2005-07-19 | 2007-01-25 | Srinivas Konakalla | Method and system for generating a business intelligence system based on individual life cycles within a business process |
WO2007054480A1 (en) * | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
AU2006327181A1 (en) * | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
JP2009535393A (ja) * | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
WO2009140517A1 (en) * | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2009140519A1 (en) * | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
-
2008
- 2008-06-23 SI SI200832113T patent/SI3184527T1/sl unknown
- 2008-06-23 EP EP16195618.0A patent/EP3184527B1/en active Active
- 2008-06-23 US US12/144,354 patent/US8163761B2/en active Active
- 2008-06-23 EP EP19211630.9A patent/EP3663295A1/en not_active Withdrawn
- 2008-06-23 JP JP2010513485A patent/JP2010530901A/ja not_active Withdrawn
- 2008-06-23 CN CN200880103802.8A patent/CN101801362B/zh not_active Expired - Fee Related
- 2008-06-23 CN CN201510111699.3A patent/CN104825457B/zh not_active Expired - Fee Related
- 2008-06-23 WO PCT/US2008/067901 patent/WO2009002933A1/en active Application Filing
- 2008-06-23 EP EP08771748.4A patent/EP2170309B1/en active Active
- 2008-06-23 CA CA2691468A patent/CA2691468C/en not_active Expired - Fee Related
- 2008-06-23 AU AU2008268463A patent/AU2008268463B2/en not_active Ceased
- 2008-06-23 CA CA2962043A patent/CA2962043A1/en not_active Abandoned
- 2008-06-23 CN CN201310718872.7A patent/CN103751194B/zh not_active Expired - Fee Related
- 2008-06-23 CN CN201711272327.4A patent/CN108042542A/zh active Pending
- 2008-06-23 DK DK08771748.4T patent/DK2170309T3/en active
- 2008-06-23 ES ES08771748.4T patent/ES2609912T3/es active Active
-
2012
- 2012-02-22 US US13/402,720 patent/US20130059869A1/en not_active Abandoned
-
2014
- 2014-05-14 JP JP2014100946A patent/JP5932883B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-13 JP JP2015139797A patent/JP6258266B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-30 US US15/639,776 patent/US20180133170A1/en not_active Abandoned
- 2017-07-04 JP JP2017131268A patent/JP2017165790A/ja not_active Withdrawn
-
2019
- 2019-04-12 JP JP2019076011A patent/JP2019147808A/ja not_active Withdrawn
-
2020
- 2020-03-03 HR HRP20200357TT patent/HRP20200357T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200357T1 (hr) | Spojevi 2,6-diokso,-2,3-dihidro-1h-purina, korisni u liječenju poremećaja povezanih s aktivnošću kanala trpa1 | |
HRP20180916T1 (hr) | Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba | |
IL278297B2 (en) | Transmutable heterocyclic PTPN11 inhibitors | |
AR066958A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
AR080328A1 (es) | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros | |
HRP20170307T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA | |
HRP20120963T1 (hr) | PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI | |
JP7074750B2 (ja) | カルバモイルフェニルアラニノール化合物およびその使用 | |
JP7366002B2 (ja) | カルバモイルフェニルアラニノール類縁体およびその使用 | |
HRP20180487T1 (hr) | Upotreba flekainida kao anti-koneksinskog sredstva i metoda za potenciranje učinaka psihotropnog lijeka | |
CA2798514A1 (en) | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
HRP20210228T1 (hr) | Amidi pirola kao inhibitori alfa v integrina | |
CY1123372T1 (el) | Απο toy στοματος φαρμακευτικη συνθεση | |
HRP20090280T1 (hr) | Derivati fenoksioctene kiseline | |
AR045082A1 (es) | Compuestos de aminobenzofenona y su uso en tratamientos terapeuticos | |
CA2551178A1 (en) | Polycyclic agents for the treatment of respiratory syncytial virus infections | |
RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
HRP20100724T1 (hr) | Supstituirani biciklički derivati pirimidona | |
HRP20171692T1 (hr) | Derivati karbamat/uree | |
RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
RU2020112229A (ru) | Замещенные имидазохинолины | |
CY1120530T1 (el) | Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση | |
HRP20191869T1 (hr) | Fluoroindol derivati kao pozitivni alosterički modulatori muskarinskog m1 receptora | |
AR084637A1 (es) | Compuestos heterociclicos apropiados para el tratamiento de la dislipidemia | |
FR2934265B1 (fr) | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique |